Header Logo

Connection

Joan Merrill to Middle Aged

Back to Details
This is a "connection" page, showing publications Joan Merrill has written about Middle Aged.
Joan Merrill
Connection Strength
2.044
Middle Aged
  1. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
    View in: PubMed
    Score: 0.091
  2. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
    View in: PubMed
    Score: 0.089
  3. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes. 2019 Jun 07; 17(1):99.
    View in: PubMed
    Score: 0.075
  4. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. Arthritis Care Res (Hoboken). 2018 07; 70(7):1058-1063.
    View in: PubMed
    Score: 0.070
  5. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
    View in: PubMed
    Score: 0.069
  6. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
    View in: PubMed
    Score: 0.068
  7. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
    View in: PubMed
    Score: 0.065
  8. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
    View in: PubMed
    Score: 0.063
  9. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. Arthritis Res Ther. 2016 09 02; 18:197.
    View in: PubMed
    Score: 0.062
  10. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
    View in: PubMed
    Score: 0.058
  11. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
    View in: PubMed
    Score: 0.047
  12. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1726-32.
    View in: PubMed
    Score: 0.044
  13. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
    View in: PubMed
    Score: 0.044
  14. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.
    View in: PubMed
    Score: 0.041
  15. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
    View in: PubMed
    Score: 0.023
  16. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
    View in: PubMed
    Score: 0.022
  17. Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis Rheumatol. 2021 12; 73(12):2293-2302.
    View in: PubMed
    Score: 0.022
  18. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
    View in: PubMed
    Score: 0.022
  19. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
    View in: PubMed
    Score: 0.021
  20. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med. 2020 10; 7(1).
    View in: PubMed
    Score: 0.021
  21. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2020 10; 72(10):1734-1740.
    View in: PubMed
    Score: 0.020
  22. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
    View in: PubMed
    Score: 0.020
  23. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Rheumatol. 2020 04; 72(4):658-666.
    View in: PubMed
    Score: 0.020
  24. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020 03; 79(3):356-362.
    View in: PubMed
    Score: 0.020
  25. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020 01; 72(1):67-77.
    View in: PubMed
    Score: 0.019
  26. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020 01; 106:102340.
    View in: PubMed
    Score: 0.019
  27. Immunologic findings precede rapid lupus flare after transient steroid therapy. Sci Rep. 2019 06 13; 9(1):8590.
    View in: PubMed
    Score: 0.019
  28. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
    View in: PubMed
    Score: 0.019
  29. Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 08; 71(8):1297-1307.
    View in: PubMed
    Score: 0.019
  30. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. J Rheumatol. 2020 01; 47(1):72-81.
    View in: PubMed
    Score: 0.019
  31. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019 02; 71(2):281-289.
    View in: PubMed
    Score: 0.018
  32. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. J Rheumatol. 2019 05; 46(5):492-500.
    View in: PubMed
    Score: 0.018
  33. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019 07; 78(7):1010-1012.
    View in: PubMed
    Score: 0.018
  34. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken). 2018 10; 70(10):1478-1487.
    View in: PubMed
    Score: 0.018
  35. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
    View in: PubMed
    Score: 0.017
  36. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017 12 22; 19(1):287.
    View in: PubMed
    Score: 0.017
  37. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
    View in: PubMed
    Score: 0.017
  38. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017 12; 69(12):1780-1788.
    View in: PubMed
    Score: 0.017
  39. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997 Jun; 24(6):1083-8.
    View in: PubMed
    Score: 0.016
  40. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.
    View in: PubMed
    Score: 0.016
  41. Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. 2017 03; 78:70-78.
    View in: PubMed
    Score: 0.016
  42. Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 02; 69(2):376-386.
    View in: PubMed
    Score: 0.016
  43. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
    View in: PubMed
    Score: 0.016
  44. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
    View in: PubMed
    Score: 0.016
  45. Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. Arthritis Rheumatol. 2016 09; 68(9):2200-9.
    View in: PubMed
    Score: 0.015
  46. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
    View in: PubMed
    Score: 0.015
  47. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
    View in: PubMed
    Score: 0.015
  48. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
    View in: PubMed
    Score: 0.014
  49. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015 Aug 04; 163(3):153-63.
    View in: PubMed
    Score: 0.014
  50. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015 Jul; 67(7):1837-47.
    View in: PubMed
    Score: 0.014
  51. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
    View in: PubMed
    Score: 0.014
  52. Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun. 2015 Jul; 61:29-35.
    View in: PubMed
    Score: 0.014
  53. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
    View in: PubMed
    Score: 0.014
  54. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):128-35.
    View in: PubMed
    Score: 0.014
  55. Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol. 2015 Feb 01; 194(3):940-9.
    View in: PubMed
    Score: 0.014
  56. Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol. 2014 Dec; 66(12):3404-12.
    View in: PubMed
    Score: 0.014
  57. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
    View in: PubMed
    Score: 0.014
  58. Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis. 2016 Jan; 75(1):242-52.
    View in: PubMed
    Score: 0.013
  59. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1167-76.
    View in: PubMed
    Score: 0.013
  60. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol. 2014 Jul; 66(7):1888-99.
    View in: PubMed
    Score: 0.013
  61. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74(9):1706-13.
    View in: PubMed
    Score: 0.013
  62. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol. 2014 May; 41(5):875-80.
    View in: PubMed
    Score: 0.013
  63. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015 Aug; 74(8):1530-6.
    View in: PubMed
    Score: 0.013
  64. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
    View in: PubMed
    Score: 0.013
  65. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov; 65(11):2887-97.
    View in: PubMed
    Score: 0.013
  66. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
    View in: PubMed
    Score: 0.013
  67. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013 Nov; 40(11):1875-80.
    View in: PubMed
    Score: 0.013
  68. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013 Jun; 43:78-84.
    View in: PubMed
    Score: 0.012
  69. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89.
    View in: PubMed
    Score: 0.012
  70. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013; 15(6):R212.
    View in: PubMed
    Score: 0.012
  71. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 2012 Nov; 64(11):3687-94.
    View in: PubMed
    Score: 0.012
  72. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012 Sep; 71(9):1502-9.
    View in: PubMed
    Score: 0.011
  73. Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. J Autoimmun. 2012 May; 38(2-3):J216-22.
    View in: PubMed
    Score: 0.011
  74. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan; 64(1):132-7.
    View in: PubMed
    Score: 0.011
  75. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
    View in: PubMed
    Score: 0.011
  76. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 2011 Sep; 63(9):2755-63.
    View in: PubMed
    Score: 0.011
  77. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011 Aug; 63(8):2396-406.
    View in: PubMed
    Score: 0.011
  78. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1752-7.
    View in: PubMed
    Score: 0.011
  79. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011 May; 6(5):593-601.
    View in: PubMed
    Score: 0.011
  80. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Jun; 70(6):961-7.
    View in: PubMed
    Score: 0.011
  81. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(4):R146.
    View in: PubMed
    Score: 0.010
  82. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun; 62(6):881-7.
    View in: PubMed
    Score: 0.010
  83. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
    View in: PubMed
    Score: 0.010
  84. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
    View in: PubMed
    Score: 0.010
  85. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010 Mar; 69(3):529-35.
    View in: PubMed
    Score: 0.009
  86. Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford). 2009 May; 48(5):513-9.
    View in: PubMed
    Score: 0.009
  87. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
    View in: PubMed
    Score: 0.009
  88. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008 May 15; 59(5):721-9.
    View in: PubMed
    Score: 0.009
  89. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar; 58(3):843-53.
    View in: PubMed
    Score: 0.009
  90. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401-9.
    View in: PubMed
    Score: 0.008
  91. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):953-62.
    View in: PubMed
    Score: 0.007
  92. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004 Dec; 31(12):2390-4.
    View in: PubMed
    Score: 0.007
  93. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004 Jan; 121(1):142-9.
    View in: PubMed
    Score: 0.006
  94. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol. 2003 Jun-Dec; 10(2-4):203-11.
    View in: PubMed
    Score: 0.006
  95. Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 2003 Mar; 48(3):737-45.
    View in: PubMed
    Score: 0.006
  96. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
    View in: PubMed
    Score: 0.006
  97. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998; 7(5):355-60.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.